After eight years of suing Veeva, IQVIA makes it the enterprise standard
IQVIA has standardized Veeva's trial-operations software 14 months after settling eight years of litigation, with no price and no scope disclosed. Veeva's Boston summit this week and its November 5 investor day decide what the concession books.
Vincent Jiang · 2 min read
Eight years in court, then an enterprise standard
On October 13, 2026, IQVIA−0.86% — IQVIA, down 0.86 percent today (NYSE: IQV), the clinical research business with roughly 94,000 employees in more than 100 countries, named four Veeva applications, CTMS for trial management, eTMF for trial documents, Study Startup and Site Connect, enterprise standard across its clinical development studies 1. The buyer's quote came from Richard Staub, president of Research and Development Solutions at IQVIA. His company spent 2017 to 2025 suing Veeva+1.89% — Veeva, up 1.89 percent today, until an August 2025 settlement between the two former rivals dismissed all claims and counterclaims with no damages paid by either side 234. The company that fought Veeva in court for eight years now runs its trial operations on it.
The border runs through data capture
What IQVIA did not standardize matters as much. Customers, Staub said, retain "the flexibility to choose the EDC, RTSM, and eCOA technologies and solutions that best meet their needs, including IQVIA's innovative capabilities": electronic data capture, randomization and trial supply, and patient outcome reporting, the layer where IQVIA still sells rivals to Veeva 15. Neither company disclosed a price, a deployment timeline, or whether "enterprise standard" covers IQVIA's existing book of trials or only new studies 25.
The revenue machine underneath
Veeva (NYSE: VEEV), with more than 1,500 customers, booked $927.96 million of revenue in the quarter ended July 31, 2026, up 17.6% year over year, with subscription revenue of $766.76 million, up 16.3% 16. Operating income climbed 40.4% to $275.02 million, helped by a year-ago quarter that carried litigation settlement charges 6. Revenue has risen every quarter through the fight, the settlement and the deal 8.
Veeva's quarterly revenue rose through the IQVIA fight, the settlement and the deal
Data
| Revenue | |
|---|---|
| Q3 '23 | $616.51M |
| Q4 '23 | $630.62M |
| Q1 '24 | $650.35M |
| Q2 '24 | $676.18M |
| Q3 '24 | $699.21M |
| Q4 '24 | $720.89M |
| Q1 '25 | $759.04M |
| Q2 '25 | $789.08M |
| Q3 '25 | $811.24M |
| Q4 '25 | $835.95M |
| Q1 '26 | $882.95M |
| Q2 '26 | $927.96M |
A flat stock, a $75 spread in targets
VEEV traded flat the day after the announcement and is up 35.1% this year against the S&P 500's 13.8%, on a $47.9 billion market value 5. Barclays raised its target to $360 on October 19, 2026, Oppenheimer held $325 on October 15, and the consensus stood at $284.88 on October 10 76. The spread between them is the disagreement over what IQVIA's concession is worth.
Street targets on Veeva spread $75 after the IQVIA deal
Data
| Value | |
|---|---|
| Consensus, 10 Oct | $284.88 |
| Oppenheimer, 15 Oct | $325 |
| Barclays, 19 Oct | $360 |
Boston answers scope, November 5 prices it
Both companies appear at Veeva's R&D and Quality Summit in Boston on October 20 and 21, 2026, the first venue where the scope question can surface 12. Veeva's virtual investor day follows on November 5, covering its industry cloud of applications, agents, data and consulting 6. The number to watch: whether IQVIA standardization appears in bookings guidance.
Deepdive
AI-generated from this story and its cited sources. Not investment advice.
